Shibuya T, Morioka E, Taniguchi S, Ohhara N, Okamura S, Niho Y
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Leuk Res. 1987;11(10):851-4. doi: 10.1016/0145-2126(87)90128-7.
The effect of a small dose of aclacinomycin-A (ACR) was examined in two patients with refractory anemia (RA) and two with refractory anemia with excess of blasts in transformation (RAEB-t). ACR (7 or 14 mg/m2) was given for 10 days in a 2-h per day drip infusion. Clinical symptoms and laboratory data improved in 3 of these 4 patients. In a patient with RA, marked increase in reticulocytes and elevation of the hemoglobin level from 6 to 9 g/dl was observed after two courses of ACR therapy. In two with RAEB-t, Auer's rod bearing cells disappeared in the bone marrow and megaloblastic change of the erythroblasts was diminished in one patient. Hemoglobin levels rose from 4.7 to 10 g/dl in one, and platelets and WBC increased in another. No effect was seen in a patient with RA. The cytoreductive effect of ACR was minor compared to the therapy with small dose of cytosine arabinoside (Ara-C). Therefore, ACR warrants further consideration for the treatment of patients with MDS.
研究了小剂量阿克拉霉素 -A（ACR）对两名难治性贫血（RA）患者和两名难治性贫血伴原始细胞过多转化（RAEB -t）患者的疗效。ACR（7或14mg/m²）以每天2小时静脉滴注的方式给药10天。这4名患者中有3名的临床症状和实验室数据有所改善。在一名RA患者中，经过两个疗程的ACR治疗后，网织红细胞显著增加，血红蛋白水平从6g/dl升至9g/dl。在两名RAEB -t患者中，一名患者骨髓中含奥氏小体的细胞消失，成红细胞的巨幼样变减轻。一名患者的血红蛋白水平从4.7g/dl升至10g/dl，另一名患者的血小板和白细胞增加。一名RA患者未见疗效。与小剂量阿糖胞苷（Ara -C）治疗相比，ACR的细胞减灭作用较小。因此，ACR在骨髓增生异常综合征患者的治疗中值得进一步考虑。
